NCT05516589View on ClinicalTrials.gov

Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 12, 2022

Primary Completion Date

October 29, 2023

Study Completion Date

December 31, 2024

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Nab-paclitaxel

260mg/m\^2 IV Q3W

DRUG

Cisplatin

75mg/m\^2 IV Q3W

BIOLOGICAL

Tislelizumab

200mg IV Q3W

DRUG

Afatinib

30mg PO QD

Trial Locations (1)

610041

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER